Fundraising Fox
Immventionthera
Chapel Hill, US · Founded 2017 · 14 employees on LinkedIn · 3 known investors
Find your way into Immventionthera
Sign up to see every warm intro you have to Immventionthera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immventionthera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions. The biotech company is working in collaboration with Novo Nordisk.
Founders & leadership
Immventionthera was founded in 2017 by Jenny Ting.
Board
Investors · 3
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$8.9M disclosed across 2 rounds · 2020–2022
▶$2MraisedJan 2023 · 4 investors · BiotechnologyRule 506(b)
- Jenny TingDirector
- Marilyn ThompsonExecutive Officer
- Mark VellecaDirector
- Anil GoyalExecutive Officer, Director
- Lev OsherovichDirector
- Benjamin ScruggsDirector
- Matthew CohenDirector
- Offering amount
- $4M
- Amount sold
- $2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.9MraisedNov 2021 · 5 investors · BiotechnologyRule 506(b)
- Matthew CohenDirector
- Anil GoyalExecutive Officer, Director
- Lev OsherovichDirector
- Jenny TingDirector
- Benjamin ScruggsDirector
- Mark VellacaDirector
- Offering amount
- $6.9M
- Amount sold
- $6.9M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Immventionthera went on to found or lead other companies.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $277.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Immventionthera do?
- Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions. The biotech company is working in collaboration with Novo Nordisk.
- Who founded Immventionthera?
- Immventionthera was founded by Jenny Ting in 2017.
- Who are Immventionthera's investors?
- Immventionthera's investors include Delin Ventures, Hatteras Venture Partners, OUP (Osage University Partners).
- How much funding has Immventionthera raised?
- Immventionthera has disclosed $8.9M raised across 2 rounds.
- Where is Immventionthera headquartered?
- Immventionthera is headquartered in Chapel Hill, US.